Biopharmaceutical developer AntriaBio, Inc. announced it will site its new manufacturing and laboratory facility in Louisville, Colorado. According to AntriaBio, the comprehensive facility will allow the company to conduct research as well as manufacture microspheres for its lead product candidate, AB101, a once-weekly basal insulin treatment for diabetes.
Located just outside of Boulder, Colorado, the facility’s approximately 27,000 square feet will encompass laboratory space, manufacturing suites and office space and house the state-of-the-art laboratory and manufacturing equipment AntriaBio acquired after purchasing PR Pharmaceuticals, Inc.'s intellectual property and assets in 2013. According to industry reports, PR Pharmaceuticals’ AB101 was in animal trials before it shuttered its Fort Collins, Colorado facility in the wake of bankruptcy proceedings in 2008.
"Establishing our manufacturing and research presence,” says Nevan Elam, AntriaBio's chairman and CEO, “is an exciting and critical step forward for the Company, as we are now poised to work as an integrated team to make clinical material for AB101 and advance that program through the next phase of development." The Company's corporate headquarters will continue to be located in Menlo Park, California.
Focused on developing novel therapeutics to treat patients with diabetes and metabolic disease, AntriaBio says its development strategy combines FDA approved pharmaceutical agents with its proprietary delivery technology.